These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34009323)

  • 61. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level.
    Grabner M; Winegar DA; Punekar RS; Quimbo RA; Cziraky MJ; Cromwell WC
    Am J Cardiol; 2017 Feb; 119(3):404-409. PubMed ID: 27887691
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparing the cost-effectiveness of four novel risk markers for screening asymptomatic individuals to prevent cardiovascular disease (CVD) in the US population.
    van Kempen BJ; Ferket BS; Steyerberg EW; Max W; Myriam Hunink MG; Fleischmann KE
    Int J Cardiol; 2016 Jan; 203():422-31. PubMed ID: 26547049
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
    Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
    Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
    Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
    Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
    Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
    Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.
    Heeg B; Damen J; Van Hout B
    Pharmacoeconomics; 2007; 25(12):1063-82. PubMed ID: 18047390
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost effectiveness of case-finding strategies for primary prevention of cardiovascular disease: a modelling study.
    Crossan C; Lord J; Ryan R; Nherera L; Marshall T
    Br J Gen Pract; 2017 Jan; 67(654):e67-e77. PubMed ID: 27821671
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness of statin therapy for secondary prevention among patients with coronary artery disease and baseline LDL-C 70-100 mg/dL in Taiwan.
    Lin FJ; Shyu KG; Hsieh IC; Huey-Herng Sheu W; Tu ST; Yeh SJ; Chen CI; Lu KC; Wu CC; Shau WY; Inocencio TJ; Wen YC; Yeh HI
    J Formos Med Assoc; 2020 May; 119(5):907-916. PubMed ID: 32081563
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
    Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
    Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
    Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
    J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.
    Critselis E; Vlahou A; Stel VS; Morton RL
    Nephrol Dial Transplant; 2018 Mar; 33(3):441-449. PubMed ID: 29106632
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: An Australian perspective.
    Ademi Z; Zomer E; Tonkin A; Liew D
    Int J Cardiol; 2018 Nov; 270():54-59. PubMed ID: 30220379
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical effectiveness and cost-effectiveness results from the randomised controlled Trial of Oral Mandibular Advancement Devices for Obstructive sleep apnoea-hypopnoea (TOMADO) and long-term economic analysis of oral devices and continuous positive airway pressure.
    Sharples L; Glover M; Clutterbuck-James A; Bennett M; Jordan J; Chadwick R; Pittman M; East C; Cameron M; Davies M; Oscroft N; Smith I; Morrell M; Fox-Rushby J; Quinnell T
    Health Technol Assess; 2014 Oct; 18(67):1-296. PubMed ID: 25359435
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.